Related Experiment Video
Updated: Aug 5, 2026
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
Long-Term Outcome of Third Myeloablative Allogeneic Stem Cell Transplantation Using Unrelated Cord Blood: A Case
Jun Ooi1, Seiko Kato2, Takaaki Konuma2
1Department of Transfusion Medicine and Cell-processing, Teikyo University School of Medicine, Tokyo, Japan; Department of Clinical Laboratory Science, Teikyo University, Tokyo, Japan.
Abstract:
Although a second allogeneic stem cell transplantation (SCT2) may cure leukemia relapse after the first allogeneic SCT (SCT1), relapse frequently occurs after SCT2. Recently, several reports on the outcomes of the third allogeneic SCT (SCT3) in patients with relapse after SCT2 have been published. However, no reports have detailed the long-term survival of patients with myeloablative SCT3 using unrelated cord blood (CB). Here, we report the results of our clinical experience in a patient with acute myeloid leukemia (AML) treated with SCT3 using CB after myeloablative conditioning. The patient remains alive and disease-free for 16.8 years after SCT3. To our knowledge, this patient is the longest survivor of AML after SCT3.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...